Study guide
4.2 Host and Environmental Risk Factors for Infection
Board Certified Infectious Diseases Pharmacist BCIDP
Track your progress as you read
Finished sections get a check mark.
1 Causes of Infectious Diseases
1.1 Bacterial Pathogens: Gram-Positive, Gram-Negative, and Atypical Organisms 1.2 Viral Pathogens: Respiratory, Herpesviruses, Hepatitis, and Emerging Viruses 1.3 Fungal Pathogens: Yeasts, Molds, and Dimorphic Fungi 1.4 Parasitic and Vector-Borne Pathogens: Protozoa and Helminths
2 Microbiology Diagnostics, Resistance & Host Response
2.1 Diagnostic Microbiology: Phenotypic, Molecular, and Rapid Diagnostic Methods 2.2 Molecular Mechanisms of Antimicrobial Resistance 2.3 Microbial Virulence Factors, Toxins, and Biofilm Dynamics 2.4 Host Immune Response to Infection and Immunopathology
3 Clinical Assessment & Diagnostic Evaluation
3.1 Clinical Assessment, Infection Screening, and Severity Stratification 3.2 Diagnostic Biomarkers and Clinical Laboratory Interpretation 3.3 Social Determinants of Health and Disparities in Infectious Diseases
4 Pharmacokinetics, Pharmacodynamics & Special Populations
4.1 Pharmacokinetic and Pharmacodynamic Optimization of Antimicrobials 4.2 Host and Environmental Risk Factors for Infection 4.3 Antimicrobial Dosing and Considerations in Special Populations
5 Respiratory and Skin/Soft Tissue Infections
5.1 Pharmacotherapy of Upper and Lower Respiratory Tract Infections 5.2 Pharmacotherapy of Skin and Soft Tissue Infections
6 Cardiovascular, Bone, and Joint Infections
6.1 Pharmacotherapy of Infective Endocarditis and CIED Infections 6.2 Pharmacotherapy of Osteomyelitis, Septic Arthritis, and PJI
7 Central Nervous System and Abdominal Infections
7.1 Pharmacotherapy of Central Nervous System Infections 7.2 Pharmacotherapy of Intra-abdominal, Hepatic, and GI Infections
8 Urologic, Gynecologic, and Sexually Transmitted Infections
8.1 Pharmacotherapy of Urinary Tract and Gynecologic Infections 8.2 Pharmacotherapy of Sexually Transmitted Infections
9 HIV Infection and Opportunistic Infections
9.1 Antiretroviral Therapy and Management of HIV-1 Infection 9.2 Prophylaxis and Management of HIV-Associated Opportunistic Infections
10 Infections in Immunocompromised Hosts and Complex Syndromes
10.1 Infections in Solid Organ Transplant and Hematologic Malignancy 10.2 Sepsis, Septic Shock, and Systemic Complications
11 Medication Administration and Adjunctive Therapies
11.1 Antimicrobial Administration, Vascular Access, and Stability 11.2 Adjunctive Pharmacotherapies and Supportive Care in Serious Infections 11.3 Assessment of Therapeutic Outcomes and Infection Failure
12 Therapeutic Drug Monitoring, Toxicity, and De-escalation
12.1 Therapeutic Drug Monitoring and Precision Pharmacokinetics 12.2 Antimicrobial Adverse Drug Events and High-Risk Drug Interactions 12.3 Antimicrobial De-escalation and IV-to-Oral Transition Strategies
13 Care Transitions, Patient Counseling & Travel Medicine
13.1 Outpatient Parenteral and Complex Oral Antimicrobial Therapy (OPAT/COPAT) 13.2 Patient and Caregiver Counseling, Education, and Adherence 13.3 Travel Medicine, Immunizations, and Prophylactic Regimens
14 Antimicrobial Stewardship Operations, Metrics & Resistance
14.1 Antimicrobial Stewardship Core Elements and Regulatory Mandates 14.2 Stewardship Metrics: Days of Therapy (DOT), DDD, and SAAR 14.3 Surveillance and Tracking of Antimicrobial Resistance Patterns 14.4 Cumulative Antibiogram Construction and CLSI M39 Analysis
15 Formulary Management, Infection Prevention & Population Health
15.1 Antimicrobial Formulary Management and Restriction Strategies 15.2 Public Health, Disease Reporting, and Adult Immunization Strategies 15.3 Healthcare Infection Prevention and Environmental Transmission
16 Literature Evaluation, Informatics & Quality Improvement
16.1 Infectious Diseases Information Resources, Databases, and Clinical Guidelines 16.2 Critical Literature Evaluation and Biostatistical Interpretation 16.3 Quality Improvement Methodologies and Medication Safety in ID 16.4 Clinical Informatics, Decision Support Systems, and Automated Alerts
4.2 Host and Environmental Risk Factors for Infection
Key Takeaways Explain This Topic AI
Foreign biomaterials dramatically lower the minimal bacterial inoculum needed to establish infection, predominantly via staphylococcal polysaccharide intercellular adhesin (PIA) biofilm production that confers antimicrobial tolerance.
Central line-associated bloodstream infections (CLABSI) caused by Staphylococcus aureus, Pseudomonas aeruginosa, Candida species, or multidrug-resistant pathogens mandate prompt catheter removal rather than line salvage.
Hyperglycemia and diabetic ketoacidosis impair neutrophil chemotaxis, phagocytosis, and oxidative burst, while free serum iron availability fuels lethal angioinvasive mucormycosis.
Anatomical or functional asplenia creates life-threatening vulnerability to encapsulated bacteria (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae) and intraerythrocytic or fastidious organisms (Babesia, Capnocytophaga canimorsus), manifesting as hyperacute overwhelming post-splenectomy infection (OPSI).
Environmental and zoonotic exposures dictate specific empiric coverage, such as amoxicillin-clavulanate for Pasteurella multocida from animal bites, and third-generation cephalosporins plus doxycycline for Vibrio vulnificus after marine exposure in cirrhotic patients.
Last updated: October 2026
Host and Environmental Risk Factors for Infection
Susceptibility to infectious diseases reflects the dynamic interplay between pathogen virulence, inoculum size, and host immune competence. When natural epithelial barriers are breached or immune surveillance mechanisms are blunted by chronic disease, the minimal infective dose drops precipitously. Infectious diseases specialists must identify patient-specific anatomic, metabolic, and environmental vulnerabilities to design targeted diagnostic investigations, direct appropriate source control, and select effective empiric antimicrobial therapy.
- Anatomical and Barrier Disruption: Foreign Bodies and Invasive Devices
- The Foreign Body Effect and Biofilm Pathophysiology
The presence of an artificial foreign body (prosthetic joint, mechanical valve, vascular graft, central line) reduces the minimal inoculum of Staphylococcus aureus required to establish infection by more than 10,000-fold (from 10^6 CFU to <100 CFU). Foreign biomaterials are rapidly coated with host extracellular matrix proteins (fibronectin, fibrinogen, vitronectin, collagen), providing docking ligands for bacterial surface adhesins ( MSCRAMMs —microbial surface components recognizing adhesive matrix molecules). Phase 1: Reversible Adhesion Phase 2: Irreversible Binding Phase 3: Maturation & EPS Matrix Phase 4: Dispersal
- Bacteria MSCRAMMs bind host Biofilm Matrix (PIA/eDNA) Bacteremic Shower
- ▼ ligands Metabolically Dormant Persisters Metastatic Foci
- ○ ○ ○ ○ ●───●───●───● ████████████████████████ ○ ○
- ───────────────────── ───────────────────── ───────────────────────── ─────── ───────
- Prosthetic Surface Prosthetic Surface Prosthetic Surface Prosthetic Surface
Biofilm formation proceeds through four discrete stages:
Reversible Attachment: Planktonic bacteria contact the protein-conditioned biomaterial via electrostatic and hydrophobic interactions.
Irreversible Binding: Bacterial adhesins lock onto host proteins; in staphylococci, the icaADBC operon is transcribed, synthesizing polysaccharide intercellular adhesin (PIA) , a linear beta-1,6-linked glucosaminoglycan that glues cells together.
Maturation and Matrix Secretion: Microcolonies encase themselves in an extracellular polymeric substance (EPS) matrix composed of exopolysaccharides, extracellular DNA (eDNA), and amyloid fibers. Fluid channels circulate nutrients, and metabolic gradients establish an anaerobic, acidic core.
Phenotypic Tolerance and Persister Cells: Deep within the biofilm, bacteria downregulate metabolic activity, entering a non-dividing, stationary-phase "persister" state. Because cell-wall active agents (beta-lactams, vancomycin) require active cell division and peptidoglycan cross-linking to exert bactericidal activity, persisters exhibit profound phenotypic tolerance (MICs can increase 100- to 1,000-fold despite genetic susceptibility).
Detachment and Dispersal: Enzymatic cleavage of the matrix releases planktonic bacteria, producing recurrent bacteremia, systemic sepsis, and metastatic seeding.
Important
Eradication of staphylococcal hardware infections requires biofilm-penetrating antimicrobials. Rifampin inhibits bacterial DNA-dependent RNA polymerase and demonstrates exceptional activity against non-dividing biofilm persisters. However, rifampin must never be used as monotherapy ; single-agent use selects for rapid, high-level resistance via point mutations in the rpoB gene within 48 to 72 hours. It must always be combined with an active companion agent (e.g., cefazolin, nafcillin, vancomycin, or ciprofloxacin) and initiated only after bacteremia has cleared.
Clinical Syndromes of Foreign Body Infections
Foreign Body / Device Dominant Pathogens Pathophysiological Hallmarks Management & Surgical Principles
Prosthetic Joint (PJI) S. aureus , S. epidermidis , Cutibacterium acnes (shoulder arthroplasty), Gram-negative bacilli Early (<3 mo post-op): surgical seeding ( S. aureus ); Delayed (3–24 mo): low-virulence biofilm (CoNS, C. acnes ); Late (>24 mo): hematogenous seeding DAIR (Debridement, Antibiotics, Implant Retention) for acute symptoms (<3 weeks) and well-fixed implant; otherwise 1-stage or 2-stage exchange arthroplasty ; add rifampin for staphylococci
Prosthetic Heart Valve (PVE) Early (<1 yr): S. epidermidis (>80% methicillin-resistant), S. aureus , fungi; Late (>1 yr): resembles native valve ( S. viridans , MSSA, enterococci) Biofilm on sewing ring, valve ring abscess, dehiscence, paravalvular leak, conduction blocks Early PVE requires triple therapy: Vancomycin + Gentamicin (first 2 weeks) + Rifampin for ≥ 6 weeks; urgent valve replacement for hemodynamic compromise or abscess
Vascular Graft S. aureus , S. epidermidis , Pseudomonas aeruginosa , enteric Gram-negatives Early (<4 mo): perioperative contamination; Late (>4 mo): bacteremic seeding, aortoenteric fistula formation Complete graft excision with extra-anatomic bypass is standard; prolonged bactericidal suppression if inoperable
Ventriculoperitoneal (VP) Shunt S. epidermidis , S. aureus , C. acnes , enteric Gram-negative rods Colonization during surgical placement; tracked retrograde colonization from distal catheter Shunt removal with external ventricular drain (EVD) placement + systemic/intraventricular antimicrobials; new shunt placed only after CSF sterilizes
- Invasive Vascular Lines and Catheter-Associated Infections Extraluminal Route Intraluminal Route
- (Dominant in short-term lines <14 days) (Dominant in long-term lines >14 days)
- Skin Flora Hub Contamination
- (S. aureus, S. epidermidis) (Contaminated hands/infusates)
- │ │
- ▼ ▼
- Migrates down insertion tract Travels inside lumen to tip
- │ │
- └───────────────────────┬────────────────────────────────┘
- ▼
- Fibrin Sheath & Biofilm at Tip
- │
- ▼
- CLABSI & Metastatic Seeding
CLABSI Pathogenesis: In short-term central venous catheters (CVCs; <14 days), extraluminal migration of skin microorganisms along the external catheter tract is the dominant route. In long-term catheters (>14 days, e.g., Hickman, Port-a-Cath, PICC), intraluminal contamination via hub manipulation dominates. Risk by site: Femoral (highest bacterial burden, avoid in adults) > Internal Jugular > Subclavian (lowest infection rate).
Mandatory Catheter Removal Criteria: Immediate line removal is required for:
Staphylococcus aureus or Candida species bacteremia/fungemia.
Pseudomonas aeruginosa , multidrug-resistant Gram-negative rods, or Acinetobacter .
Catheter-site tunnel infection or port-pocket abscess.
Septic thrombophlebitis, endocarditis, or metastatic seeding.
Persistent bacteremia >72 hours despite appropriate targeted antimicrobial therapy.
Catheter Salvage Criteria: Reserved strictly for uncomplicated bacteremia involving coagulase-negative staphylococci or enterococci in patients with limited venous access, utilizing systemic antimicrobials combined with antibiotic lock therapy (e.g., vancomycin or ethanol locks dwell for 12–24 hours).
Other Device-Related Infections
Endotracheal Tubes and VAP: The tube disrupts cough and mucociliary clearance, while pooled secretions above the cuff leak into the bronchial tree via microaspiration. Biofilms coat the tube lumen. VAP Prevention Bundles: Elevating head of bed 30°–45°, subglottic secretion drainage, daily sedation interruptions with spontaneous breathing trials, and avoidance of unnecessary acid suppression.
Indwelling Urinary Catheters and CAUTI: Extraluminal ascent via periurethral mucous films occurs during catheter insertion; intraluminal retrograde ascent follows drainage bag contamination. Asymptomatic Bacteriuria (ASB) must never be treated with antimicrobials in catheterized patients (exceptions: pregnancy, planned urological procedures with mucosal trauma); treatment does not prevent CAUTI and drives antimicrobial resistance.
Extensive Thermal Burns: Loss of the stratum corneum barrier and microvascular thrombosis create avascular, protein-rich eschar , a potent culture medium. Neutrophil chemotaxis and oxidative killing are severely impaired, leading to invasive burn sepsis caused by Pseudomonas aeruginosa (ecthyma gangrenosum-like lesions), S. aureus , and opportunistic molds ( Aspergillus , Mucorales ).
- Chronic Underlying Comorbidities and Immune Dysfunction
- Diabetes Mellitus and Metabolic Perturbations
Hyperglycemia drives systemic immune blunting through multiple biochemical cascades:
Neutrophil Dysfunction: Non-enzymatic glycation of immunoglobulins and cell-surface receptors impairs neutrophil rolling, chemotaxis, adherence, and phagocytosis. Blunted intracellular generation of reactive oxygen species (superoxide anion, hydrogen peroxide) diminishes bactericidal and fungicidal oxidative burst.
Micro- and Macrovascular Disease: Diabetic endarteritis induces local tissue ischemia, hypoxia, and impaired delivery of circulating humoral defense factors and systemically administered antimicrobials.
Specific Infectious Syndromes:
Diabetic Foot Infections (DFI): Peripheral neuropathy and microvascular disease produce malperforans ulcers. Moderate-to-severe infections are characteristically polymicrobial , involving aerobic Gram-positive cocci ( S. aureus , Group B streptococci), Enterobacterales ( E. coli , Proteus ), and obligate anaerobes ( Bacteroides fragilis , Peptostreptococcus ).
Malignant (Necrotizing) External Otitis: Invasive Pseudomonas aeruginosa infection of the external auditory canal that spreads to the temporal bone and skull base, causing cranial nerve palsies (CN VII, IX, X, XI).
Emphysematous Pyelonephritis / Cholecystitis: Gas-forming infections (primarily E. coli and K. pneumoniae ) fueled by high tissue glucose concentrations enabling anaerobic mixed-acid fermentation. Diabetic Ketoacidosis (DKA)
- │
- ▼
- Systemic Acidosis (pH < 7.35) & Hyperglycemia
- │
- ▼
- Dissociation of Iron from Host Serum Transferrin
- │
- ▼
- Abundant Free Serum Iron Availability
- │
- ▼
- Binding to Fungal Spore CotH3 Receptors & Gtr1 Iron Permeases
- │
- ▼
- Rapid Hyphal Germination of Rhizopus / Mucorales
- │
- ▼
- Angioinvasion ──► Thrombosis ──► Black Necrotic Facial Eschar
Warning
Rhino-Orbital-Cerebral Mucormycosis ( Rhizopus , Mucor , Lichtheimia ): In diabetic ketoacidosis (DKA), profound acidosis and hyperketonemia disrupt iron-binding proteins, releasing massive quantities of free serum iron . Mucorales fungi express high-affinity iron permeases ( Gtr1 ) and surface proteins ( CotH3 ) that bind glucose-regulated protein 78 (GRP78) on host endothelial cells. This stimulates explosive fungal proliferation, endovascular elastase release, rapid angioinvasion, extensive vessel thrombosis, and tissue infarction. Presenting features include facial pain, proptosis, ophthalmoplegia, and a black necrotic eschar on the hard palate or nasal turbinates . Immediate management mandates emergent surgical debridement of all necrotic tissue combined with high-dose liposomal amphotericin B (5 to 10 mg/kg/day) and aggressive DKA reversal.
Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD)
Uremic Immunosuppression: Uremic toxins inhibit monocyte antigen presentation, suppress T-cell blastogenesis, downregulate co-stimulatory molecules (CD80/CD86), and impair neutrophil intracellular killing.
Vascular Access Bacteremia: Arteriovenous fistulas (AVF) carry the lowest risk of infection; arteriovenous grafts (AVG) carry intermediate risk; tunneled cuffed central catheters (TCC) carry a 10-fold higher bacteremia rate. Staphylococcus aureus (MSSA and MRSA) accounts for >50% of vascular access bacteremias and carries an exceptionally high risk of metastatic complications : infective endocarditis (up to 20%), septic arthritis, and vertebral osteomyelitis/epidural abscess.
Peritoneal Dialysis (PD) Peritonitis: Defined by cloudy dialysate effluent, abdominal pain, and an effluent cell count >100 WBC/µL (with >50% polymorphonuclear leukocytes). Gram-positive skin flora ( S. epidermidis , S. aureus ) predominate, followed by enteric Gram-negatives. Intraperitoneal (IP) administration of cefazolin or vancomycin plus an aminoglycoside or cefepime is the preferred route of treatment.
Cirrhosis and Advanced Liver Failure
Pathophysiology: Advanced cirrhosis causes loss of hepatic reticuloendothelial function (macrophages/Kupffer cells fail to clear bacteria from portal blood), portosystemic shunting (allowing portal bacteremia to bypass the liver), hypocomplementemia (defective C3/C4 hepatic synthesis), and portal hypertensive enteropathy (increased intestinal permeability and bacterial translocation).
Spontaneous Bacterial Peritonitis (SBP): Monomicrobial infection of ascitic fluid occurring in the absence of a surgically treatable intra-abdominal source. Ascitic fluid analysis reveals an absolute neutrophil count (ANC) ≥ 250 cells/mm3 (0.25 x 10^9/L). Causative agents are enteric Gram-negative bacilli ( E. coli , K. pneumoniae ) or Streptococcus pneumoniae .
Therapy: Third-generation cephalosporin (IV ceftriaxone 2 g daily or cefotaxime 2 g q8h) plus intravenous albumin (1.5 g/kg within 6 hours, followed by 1.0 g/kg on day 3) to prevent circulatory dysfunction, hepatorenal syndrome, and death.
Secondary Prophylaxis: Indefinite daily oral prophylaxis with ciprofloxacin (500 mg daily) or trimethoprim-sulfamethoxazole (one DS tablet daily).
Pathogen Vulnerabilities: Extreme susceptibility to encapsulated organisms ( S. pneumoniae bacteremia) and fulminant foodborne/marine pathogens ( Vibrio vulnificus ), where transferrin saturation from hepatic iron overload allows explosive bacterial replication and septic shock.
Anatomical and Functional Asplenia
Immunological Deficit: The spleen filters poorly opsonized particles from the circulation via splenic cords and red pulp macrophages. Furthermore, marginal zone B cells generate natural IgM antibodies that initiate the classical complement cascade against polysaccharide capsules, while the spleen produces critical opsonins ( properdin and tuftsin ). Conditions conferring functional hyposplenism include sickle cell anemia (repeated splenic auto-infarctions leading to functional asplenia by age 5), celiac disease, and severe graft-versus-host disease. Loss of Spleen (Surgical Splenectomy or Sickle Cell Auto-Infarction)
- │
- ┌───────────────────────┴───────────────────────┐
- ▼ ▼
- Loss of Red Pulp Macrophages Loss of Marginal Zone IgM Memory B Cells
- (Defective filtration of poorly (Inability to generate opsonizing antibodies
- opsonized bacteria) against polysaccharide capsules)
- │ │
- └───────────────────────┬───────────────────────┘
- ▼
- Overwhelming Post-Splenectomy Infection (OPSI)
- Hyperacute septic shock, purpura fulminans, bilateral adrenal
- hemorrhage (Waterhouse-Friderichsen syndrome), >50% mortality
- │
- ┌───────────────────────┼───────────────────────┐
- ▼ ▼ ▼
- Streptococcus pneumoniae Neisseria meningitidis Haemophilus influenzae type b
- (>50-70% of OPSI) (Rapid purpura) (Pediatric risk)
Overwhelming Post-Splenectomy Infection (OPSI): A hyperacute, catastrophic septicemia characterized by initial mild flu-like symptoms that rapidly progress within hours to fulminant septic shock, disseminated intravascular coagulation (DIC), purpura fulminans, bilateral adrenal hemorrhage ( Waterhouse-Friderichsen syndrome ), and mortality >50%.
Pathogen Spectrum:
Encapsulated Bacteria: Streptococcus pneumoniae (accounts for >50–70% of OPSI), Neisseria meningitidis , and Haemophilus influenzae type b.
Zoonotic and Parasitic Threats:
Capnocytophaga canimorsus: Fastidious, filamentous Gram-negative rod found in normal canine and feline oral flora. Animal bites or scratches in an asplenic patient provoke fulminant sepsis, symmetrical peripheral gangrene, and purpura fulminans.
Babesia microti: Intraerythrocytic tick-borne protozoan ( Ixodes scapularis ). Because the spleen normally culls parasitized erythrocytes, asplenic patients experience uncontrolled parasitemia (>10–50% parasitemia), severe Coombs-negative hemolytic anemia, hemoglobinuria, renal failure, and death.
Bordetella holmesii: Can trigger invasive bacteremia mimicking pneumococcal sepsis.
Vaccine and Prophylaxis Mandates: Asplenic patients require conjugate pneumococcal vaccination ( PCV20 alone or PCV15 followed by PPSV23 ≥ 8 weeks later), meningococcal conjugates ( MenACWY plus MenB ), and H. influenzae type b ( Hib ). Patients must carry emergency standby oral antibiotics (amoxicillin-clavulanate or levofloxacin) to initiate immediately upon developing fever.
- Environmental, Occupational, and Healthcare Exposures
- Healthcare-Associated Exposures
Prior antimicrobial exposure (especially third-generation cephalosporins, fluoroquinolones, and carbapenems) destroys protective anaerobic intestinal microflora, eradicating colonization resistance. Specific exposures carry defined microbiological risks:
Recent Hospitalization (≤ 90 days) or LTCF Residence: Colonization with methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, and Clostridioides difficile .
Outpatient Hemodialysis: Clonal transmission of MRSA, multi-drug resistant Gram-negative bacilli, and bloodborne viral pathogens.
Animal, Zoonotic, and Environmental Exposure Matrix
Exposure Setting Key Pathogens Clinical Manifestations Preferred Antimicrobial Regimen
Cat or Dog Bite / Scratch Pasteurella multocida , Capnocytophaga canimorsus , Staphylococcus , Streptococcus , oral anaerobes Rapid-onset cellulitis and tenosynovitis within 12–24 hours; necrotizing infection Amoxicillin-clavulanate orally (IV ampicillin-sulbactam). Pasteurella is intrinsically resistant to cephalexin, clindamycin, and vancomycin!
Cat Scratch / Flea Feces Bartonella henselae Cat scratch disease (subacute regional lymphadenopathy), bacillary angiomatosis Azithromycin (doxycycline or rifampin alternatives)
Livestock Parturition / Dairy Coxiella burnetii (Q fever), Brucella spp. Q fever (culture-negative endocarditis, hepatitis); Brucellosis (undulant fever, sacroiliitis) Q fever: Doxycycline + Hydroxychloroquine ; Brucella: Doxycycline + Rifampin (or gentamicin)
Saltwater / Raw Oysters Vibrio vulnificus , Vibrio parahaemolyticus Hemorrhagic bullae, necrotizing fasciitis, septic shock (especially in cirrhosis/hemochromatosis) Ceftriaxone + Doxycycline (or levofloxacin)
Freshwater Laceration / Leeches Aeromonas hydrophila Cellulitis, myonecrosis, surgical leech infection; resistant to ampicillin Ciprofloxacin , Cefepime, or TMP-SMX
Aquarium Water / Fish Handling Mycobacterium marinum "Fish tank granuloma"; nodular, ulcerating lymphocutaneous lesions along lymphatic drainage Clarithromycin + Ethambutol or Rifampin; Doxycycline
Hot Tubs / Spas Pseudomonas aeruginosa Pruritic papulopustular "hot tub folliculitis"; external otitis Usually self-limiting; oral Ciprofloxacin if severe
Potable Water / Cooling Towers Legionella pneumophila Severe atypical pneumonia, hyponatremia, diarrhea, confusion Levofloxacin or Azithromycin
Bird / Bat Guano (Caves, Silos) Histoplasma capsulatum Acute/chronic pulmonary nodules, mediastinal adenopathy, disseminated histoplasmosis Liposomal amphotericin B followed by oral Itraconazole
Soil / Decaying Wood (Rivers) Blastomyces dermatitidis Pyogranulomatous pulmonary infiltrates, verrucous skin ulcerations, osteomyelitis Liposomal amphotericin B followed by Itraconazole
Dust Storms / Desert Soil (SW US) Coccidioides immitis / posadasii "Valley fever": erythema nodosum, hilar adenopathy, meningitis, cavitary nodules Fluconazole (high-dose); Liposomal amphotericin B for meningitis or severe disease
Hospital Construction / Dust Aspergillus spp., Mucorales Invasive pulmonary aspergillosis in neutropenic patients; sinus necrosis Voriconazole or Isavuconazole (Aspergillus); Liposomal amphotericin B (Mucorales)